TY  - JOUR
AU  - Inoue, Yusuke
AU  - Osman, Murat
AU  - Suda, Takafumi
AU  - Sugimura, Haruhiko
PY  - 2016
TI  - PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
JF  - Translational Cancer Research; Vol 5, Supplement 2 (August 22, 2016): Translational Cancer Research
Y2  - 2016
KW  - 
N2  - Immune checkpoint blockade has emerged as a promising and distinct treatment strategy and has caused a paradigm shift in oncology. Significant response and survival benefit have been observed in a fraction of patients who were treated with immune checkpoint inhibitors (ICIs) in several malignancies including melanoma (1-3), non-small-cell lung cancer (NSCLC) (4-7), gastric cancer (8), urothelial carcinoma (9), Hodgkin’s lymphoma (10), and head and neck squamous cell carcinoma (11).
UR  - https://tcr.amegroups.org/article/view/8810